Condition
Berger Disease
Total Trials
5
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
5Total
P 2 (3)
P 3 (2)
Trial Status
Active Not Recruiting2
Enrolling By Invitation1
Not Yet Recruiting1
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07020923Phase 2Active Not Recruiting
Monthly Dosing of Atacicept in IgAN
NCT07498335Phase 3Not Yet RecruitingPrimary
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT04716231Phase 3Active Not Recruiting
Atacicept in Subjects With IgA Nephropathy
NCT06674577Phase 2Enrolling By Invitation
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
NCT03841448Phase 2Terminated
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
Showing all 5 trials